Guidance for Chief Pharmacists and supporting documents to achieve Institutional Readiness and deployment of COVID-19 Treatments

Read first

Implementation of effective process control is essential to ensure that neutralising monoclonal antibody products are implemented safely.

COVID-19 Treatments in CMDUs

Chief Pharmacists may need to oversee and manage prescription and supply of nMABs and oral antivirals in CMDUs. Use our framework and resources to help.
Three models exist for the supply and administration of COVID-19 treatments through CMDUs. We guide through the risks and mitigations associated with each.

nMABs

Casirivimab and imdevimab (Ronapreve)

Guidance for Chief Pharmacists and supporting documents to achieve Institutional Readiness and deployment of Ronapreve

Sotrovimab (Xevudy)

Guidance for Chief Pharmacists and supporting documents to achieve Institutional Readiness and deployment of Xevudy

Oral antivirals

Oral antivirals

Oral antivirals may reduce COVID-19 symptoms, progression, transmission, hospitalisation and mortality. We guide on successful deployment for Chief Pharmacists.